Ranbaxy Gets Dibs On Generic Alzheimer's Drug

Law360, New York (September 21, 2010, 5:45 PM EDT) -- India's Ranbaxy Laboratories Ltd. has secured approval from the U.S. Food and Drug Administration to sell a generic version of Eisai Co.'s Alzheimer's treatment Aricept, scoring a win in a battle to be the first generic maker of the drug.

Aricept's patent expires on Nov. 25, after which Ranbaxy may start selling its generic version in the U.S., the FDA said, according to several India-based news sources.

Ranbaxy's key rival, Teva Pharmaceutical Industries Ltd., had its approval to sell a generic version of the drug switched...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.